Trial · NCT04898231
MIS-C Comparative Effectiveness Study
NCT04898231, Phase 2, Phase 3, Completed, University of California, San Diego; results first posted 2025-11-04
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. MIS-C Comparative Effectiveness Study. Trials, record NCT04898231. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04898231
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- MIS-C Comparative Effectiveness Study
- NCT number
- NCT04898231
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 73 participants, actual
- Lead sponsor
- University of California, San Diego
- Conditions
- Multisystem Inflammatory Syndrome-Children
- Interventions
- Infliximab, Anakinra, Methylprednisolone
- First posted
- 2021-05-24
- Last updated
- 2025-11-04
- Results first posted
- 2025-11-04
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Needing Additional Anti-inflammatory Therapy Within the First Week of First Randomization | 1 week | The three arms of the study will be compared to see which initial randomization arm (infliximab, anakinra or steroids) has the lowest rate of additional anti-inflammatory therapy within the first week of first randomization. |
| Secondary | Number of Participants With Adverse Events | 6 weeks | Of the three initial randomization arms (infliximab, steroids or anakinra), the rate of adverse events will be compared. The goal is to determine which arm has the lowest rate of adverse events. The AEs reported in the AE section include: All Cause, SAE and Others. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants Needing Additional Anti-inflammatory Therapy Within the First Week of First Randomization | 1 week | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants With Adverse Events | 6 weeks | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Needing Additional Anti-inflammatory Therapy Within the First Week of First Randomization | Infliximab | 10 | Participants | ||
| Number of Participants Needing Additional Anti-inflammatory Therapy Within the First Week of First Randomization | Methylprednisilone (steroids) | 10 | Participants | ||
| Number of Participants Needing Additional Anti-inflammatory Therapy Within the First Week of First Randomization | Anakinra | 14 | Participants | ||
| Number of Participants With Adverse Events | Infliximab | 0 | Participants | ||
| Number of Participants With Adverse Events | Methylprednisilone (steroids) | 16 | Participants | ||
| Number of Participants With Adverse Events | Anakinra | 1 | Participants |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Infliximab | 25 | |
| Overall Study | STARTED | Methylprednisilone (steroids) | 24 | |
| Overall Study | STARTED | Anakinra | 24 | |
| Overall Study | COMPLETED | Infliximab | 25 | |
| Overall Study | COMPLETED | Methylprednisilone (steroids) | 24 | |
| Overall Study | COMPLETED | Anakinra | 22 | |
| Overall Study | NOT COMPLETED | Infliximab | 0 | |
| Overall Study | NOT COMPLETED | Methylprednisilone (steroids) | 0 | |
| Overall Study | NOT COMPLETED | Anakinra | 2 |
Source ClinicalTrials.gov
Adverse events18
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Bradycardia | Cardiac disorders | Infliximab | 0 | 25 | 0 |
| other | Bradycardia | Cardiac disorders | Methylprednisilone (steroids) | 9 | 24 | 9 |
| other | Bradycardia | Cardiac disorders | Anakinra | 0 | 22 | 0 |
| other | Hallucinations | Nervous system disorders | Infliximab | 0 | 25 | |
| other | Hallucinations | Nervous system disorders | Methylprednisilone (steroids) | 1 | 24 | 1 |
| other | Hallucinations | Nervous system disorders | Anakinra | 1 | 22 | 1 |
| other | Increased ALT | Hepatobiliary disorders | Infliximab | 0 | 25 | 0 |
| other | Increased ALT | Hepatobiliary disorders | Methylprednisilone (steroids) | 2 | 24 | 2 |
| other | Increased ALT | Hepatobiliary disorders | Anakinra | 0 | 22 | 0 |
| other | Melena | Gastrointestinal disorders | Infliximab | 0 | 25 | 0 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Infliximab | 0 | 25 |
| Total, all-cause mortality | Methylprednisilone (steroids) | 0 | 24 |
| Total, all-cause mortality | Anakinra | 0 | 22 |
| Total, other adverse events | Infliximab | 0 | 25 |
| Total, other adverse events | Methylprednisilone (steroids) | 16 | 24 |
| Total, other adverse events | Anakinra | 1 | 22 |
| Total, serious adverse events | Infliximab | 0 | 25 |
| Total, serious adverse events | Methylprednisilone (steroids) | 0 | 24 |
| Total, serious adverse events | Anakinra | 0 | 22 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04898231
GET https://conductscience.org/api/trials/v1/NCT04898231/registered